Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial
Meinolf Karthaus(Evangelisches Krankenhaus Bielefeld), Peter Reichardt(Helios Hospital Berlin-Buch), George Fountzilas(Hellenic Cooperative Oncology Group), M. Biakhov(Central Clinical Hospital and Polyclinic), C. Giorgetti(Kyiv City Clinical Oncology Center), W. Baronius(Klinikum Chemnitz), Norbert Marschner(University Medical Center Freiburg), Albrecht Kretzschmar(Roche (Switzerland)), David Irwin(Alta Bates Summit Medical Center), H. Kröning(Praxis für Hämatologie und Onkologie), G. Steger(Aristotle University of Thessaloniki), A. Garin(Russian Cancer Research Center NN Blokhin), N.G.F. Abecasis(Instituto Português de Oncologia Francisco Gentil), T Südhoff(Universitätsklinikum Knappschaftskrankenhaus Bochum), C. Slabber(Life Groenkloof Hospital)
Cited by 223
Related Papers
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k